Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant bias » significant based (Expand Search), significant gap (Expand Search), significant degs (Expand Search)
significant bit » significant hits (Expand Search), significant i (Expand Search), significant anti (Expand Search)
Showing 601 - 620 results of 21,342 for search '(( ((significant bit) OR (significant bias)) decrease ) OR ( significant decrease decrease ))', query time: 0.45s Refine Results
  1. 601
    Data Sheet 2_An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease.xlsx

    Data Sheet 2_An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-m... by Christopher L. Reading (21236861)

    Published 2025
    Save to List
    Saved in:
  2. 602
    Data Sheet 1_An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease.docx

    Data Sheet 1_An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-m... by Christopher L. Reading (21236861)

    Published 2025
    Save to List
    Saved in:
  3. 603
    Path analysis diagram illustrating the associations between alexithymia, social support, anticipated stigma and patient satisfaction, with their respective correlation coefficients. Solid lines represent a significant correlation is present. Dotted lines represent non-statistically significant correlations.

    Path analysis diagram illustrating the associations between alexithymia, social support, anticipated stigma and patient satisfaction, with their respective correlation coefficients... by Keya Bibikar (22386306)

    Published 2025
    Save to List
    Saved in:
  4. 604
    P values of Kruskal–Wallis test at 95% significance level.

    P values of Kruskal–Wallis test at 95% significance level. by Fahd Saeed Alakbari (10701871)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 605
    Table 1_Increased frequencies of human Th-17 CD4+ T-cells and decreased T-regulatory cells in patients with early and advanced metabolic dysfunction-associated steatotic liver disease.docx

    Table 1_Increased frequencies of human Th-17 CD4+ T-cells and decreased T-regulatory cells in patients with early and advanced metabolic dysfunction-associated steatotic liver dise... by Elżbieta Supruniuk (16736637)

    Published 2025
    Save to List
    Saved in:
  6. 606
    Table 2_Increased frequencies of human Th-17 CD4+ T-cells and decreased T-regulatory cells in patients with early and advanced metabolic dysfunction-associated steatotic liver disease.xlsx

    Table 2_Increased frequencies of human Th-17 CD4+ T-cells and decreased T-regulatory cells in patients with early and advanced metabolic dysfunction-associated steatotic liver dise... by Elżbieta Supruniuk (16736637)

    Published 2025
    Save to List
    Saved in:
  7. 607
    Comparative Analysis of Chills Experience Across Three Groups: This table presents a detailed comparison of three groups (A, B, and C) in terms of their experiences with chills. It includes the number of participants in each group, frequency, intensity, and duration of chills, along with demographics such as gender, age, race, education level, and income. Statistical significance (p-value) is also provided for each category.

    Comparative Analysis of Chills Experience Across Three Groups: This table presents a detailed comparison of three groups (A, B, and C) in terms of their experiences with chills. It... by Felix Alexandre Schoeller (20988295)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 608
    <i>N. parisii</i> infection is not significantly changed in <i>C. elegans</i> sphingolipid biosynthesis mutants.

    <i>N. parisii</i> infection is not significantly changed in <i>C. elegans</i> sphingolipid biosynthesis mutants. by Hala Tamim El Jarkass (16625309)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 609
    Two-way ANCOVA results for Task 1. The bold values highlight statistically significant results of Task 1.

    Two-way ANCOVA results for Task 1. The bold values highlight statistically significant results of Task 1. by Mucahit Gemici (21519313)

    Published 2025
    Save to List
    Saved in:
  10. 610
    One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2.

    One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2. by Mucahit Gemici (21519313)

    Published 2025
    Save to List
    Saved in:
  11. 611
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 612
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 613
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 614
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 615
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 616
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 617
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 618
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 619
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 620
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: